BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1

CUSIP: 10806XAB8

Q1 2025 13F Holders as of 31 Mar 2025

Type / Class
Debt / NOTE 2.500% 3/1
Market price (% of par)
114.27%
Total 13F principal
$574,937,600
Principal change
+$22,051,000
Total reported market value
$656,979,517
Number of holders
44
Value change
+$27,477,843
Number of buys
21
Number of sells
26

Quarterly Holders Quick Answers

What is CUSIP 10806XAB8?
CUSIP 10806XAB8 identifies 10806XAB8 - BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q1 2025

As of 31 Mar 2025, BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 was held by 44 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $574,937,600 in principal (par value) of the bond. The largest 10 bondholders included Weiss Asset Management LP, Linden Advisors LP, BRAIDWELL LP, WOLVERINE ASSET MANAGEMENT LLC, Graham Capital Management, L.P., TENOR CAPITAL MANAGEMENT Co., L.P., Point72 Asset Management, L.P., BNP PARIBAS FINANCIAL MARKETS, 683 Capital Management, LLC, and Opti Capital Management, LP. This page lists 44 institutional bondholders reporting positions for the Q1 2025 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.